Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2005
12/22/2005US20050281910 Method for increasing pet activity
12/22/2005US20050281886 Particles for the delivery of active agents
12/22/2005US20050281885 Method for treating inflammatory bowel disease by oral administration of IL-10
12/22/2005US20050281884 Unagglomerated core/shell nanocomposite particles
12/22/2005US20050281883 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
12/22/2005US20050281882 Matrix made of a polysaccharide modified under an electron beam with a functional organosilicon compound
12/22/2005US20050281881 comprises from 2% to 55% by weight of at least one polymer which forms a gel in water, water, from 0.1% to 15% by weight of a sea algae extract, and from 1% to 85% by weight of alcohol selected from monohydric and polyhydric alcohols, each based on a total weight of the matrix; drug delivery
12/22/2005US20050281880 Methods for making injectable polymer hydrogels
12/22/2005US20050281879 Injectable gel; moderating releasing
12/22/2005US20050281877 Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
12/22/2005US20050281876 Solid dosage form for acid-labile active ingredient
12/22/2005US20050281875 Promethazine containing dosage form
12/22/2005US20050281874 Coating compositions for bitterness inhibition
12/22/2005US20050281873 Universal controlled-release composition
12/22/2005US20050281872 Enhanced compliance antiviral medicaments and methods of manufacture and use
12/22/2005US20050281871 Methods for coating substrates for pharmaceutical uses with a mixture of two film-forming coating agents
12/22/2005US20050281870 Pain management
12/22/2005US20050281868 Transdermal delivery system for statin combination therapy
12/22/2005US20050281867 Nitric oxide inducing agents
12/22/2005US20050281863 Controlled release bioactive agent delivery device
12/22/2005US20050281862 Non-aspirating transitional viscoelastics for use in surgery
12/22/2005US20050281861 Macromolecule-containing sustained release intraocular implants and related methods
12/22/2005US20050281858 Devices, articles, coatings, and methods for controlled active agent release
12/22/2005US20050281850 Cosmetic/dermatological inverse emulsions containing calcitriol and clobetasol 17-propionate
12/22/2005US20050281848 Oleaginous ointments comprising two solubilized bioactive agents for the treatment of psoriasis
12/22/2005US20050281843 Use of bioadhesives and adjuvants for the mucosal delivery of antigens
12/22/2005US20050281806 Compositions for topical enzymatic debridement
12/22/2005US20050281804 Administering human recombinant alpha -L-iduronidase, carrier and polysorbate for therapy of mucopolysaccharidosis
12/22/2005US20050281795 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
12/22/2005US20050281789 Transcutaneous and/or transdermal transport of materials
12/22/2005US20050281781 extracted yeast cell wall comprising beta-glucan, a payload molecule(e.g.polynucleotides, polypeptides, proteins, and drugs) and a payload trapping molecule ( e.g polysaccharides, polyamides, polyacrylamide, cationic and anionic polymers, detergents); both in vivo/in vitro delivery of polyload molecule
12/22/2005US20050281772 Compositions for mucosal delivery of agents
12/22/2005US20050281759 combine both whitening/stain removal of teeth with remineralization; calcium peroxyphosphate compounds are capable of releasing, in an aqueous environment, whitening and remineralization effective amounts of calcium ion, phosphate ion, and active oxygen; calcium peroxymonophosphate
12/22/2005US20050281758 Oral care compositions
12/22/2005US20050281757 Oral care film
12/22/2005US20050281756 Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
12/22/2005US20050281755 Topical foam/mousse compositions for treating psoriasis
12/22/2005US20050281754 Sprayable compositions comprising a combination of pharmaceutical active ingredients, an alcohol phase and an oily phase
12/22/2005US20050281753 Buccal, polar and non-polar spray or capsule
12/22/2005US20050281752 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
12/22/2005US20050281750 Sprayable compositions comprising a combination of pharmaceutical active agents, an alcohol phase, at least one volatile silicone and a non-volatile oily phase
12/22/2005US20050281748 Abuse-deterrent drug formulations
12/22/2005US20050279639 Coating process and apparatus with improved resistance to bacteria
12/22/2005US20050279356 Inhaler using pods
12/22/2005US20050279350 Methods and apparatus for relieving headaches, rhinitis and other common ailments
12/22/2005DE19814084B4 D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's disease and process for its preparation
12/22/2005DE10212864B4 Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung Polymer matrices comprising a mixing system for the solubilization of pharmaceutically active substances, processes for their preparation and their use
12/22/2005DE102004045186A1 Hydratisierte lamellare Phasen oder Liposomen, enthaltend ein Fettmonoamin oder ein kationisches Polymer, das die intrazelluläre Penetration begünstigt, und kosmetische oder pharmazeutische Zusammensetzungen, diese enthaltend, sowie Screeningverfahren nach einer solchen Substanz Hydrated lamellar phases or liposomes, containing a fatty mono-amine or a cationic polymer that promotes intracellular penetration, and cosmetic or pharmaceutical compositions comprising them, as well as screening methods for such substance
12/22/2005DE102004024451A1 Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten Powder formulations for inhalation which contain Enantiomerically pure beta agonists
12/22/2005DE10053267B4 Verfahren zur Herstellung von mikrosphärischen Kristalliten, danach hergestellte mikrosphärische Kristallite und deren Verwendung A process for producing microspherical crystallites which microspherical crystallites produced thereby, and their use
12/22/2005DE10042412B4 Transceiver for bus subscriber of bus system of building system engineering, has two wires, where microcontroller is connected with receiver unit over connection on one hand, which is connected to two wires of bus system
12/22/2005CA2570649A1 Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
12/22/2005CA2569836A1 Herbal compositions for prevention and treatment of rheumatic and inflammatory diseases and method of preparing the same
12/22/2005CA2569746A1 Capsule stable against mastication
12/22/2005CA2569684A1 Dry composition for oral ingestion and gel composition prepared just before use for oral ingestion
12/22/2005CA2569672A1 Polypeptides with the capacity to entrap drugs and release them in a controlled way
12/22/2005CA2569664A1 Lipid encapsulated interfering rna
12/22/2005CA2569645A1 Cationic lipids and methods of use
12/22/2005CA2569590A1 Drug having regulatory cell ligand contained in liposome
12/22/2005CA2569352A1 Morinda citrifolia-based formulation 5-lox and 15-lox
12/22/2005CA2569137A1 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
12/22/2005CA2569121A1 Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
12/22/2005CA2568625A1 System and method for transdermal delivery of an anticoagulant
12/22/2005CA2568443A1 Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihistamines
12/22/2005CA2567830A1 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
12/22/2005CA2567827A1 Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
12/22/2005CA2567063A1 Dosage form containing the active ingredient cholylsarcosine
12/22/2005CA2566771A1 Sugar coatings and methods therefor
12/22/2005CA2566559A1 Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
12/22/2005CA2566497A1 Multi-layered controlled-release methylphenidate pellet
12/22/2005CA2565262A1 Nutritional formulations
12/22/2005CA2564197A1 Activatable particles, preparations and uses
12/22/2005CA2510813A1 Injectable pharmaceutical compositions comprising sodium diclofenac and .beta.-cyclodextrin
12/21/2005EP1607407A2 Aloe pectins
12/21/2005EP1607104A1 Pressure-sensitive adhesive for percutaneous absorption, pressure-sensitive adhesive composition for percutaneous absorption, and medicinal preparation for percutaneous absorption
12/21/2005EP1607093A1 Improved delivery of multiple doses of medications
12/21/2005EP1607092A1 Release control compositions
12/21/2005EP1607088A1 Controlled release composition
12/21/2005EP1607087A1 Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
12/21/2005EP1607086A1 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
12/21/2005EP1607085A1 Sustained-release hydrogel preparation
12/21/2005EP1606997A1 Method of inhibiting freeze concentrating of substance in wet material, method of inhibiting deactivation of physiologically active substance, and process for producing lyophilizate or frozen matter having component homogeneously diffused therein
12/21/2005EP1606381A2 Coated enzyme granules
12/21/2005EP1606298A2 Direct compressible trehalose solids
12/21/2005EP1606231A1 Process for preparation of clopidogrel, its salts and pharmaceutical compositions
12/21/2005EP1605996A2 Medical devices with enhanced ultrasonic visibility
12/21/2005EP1605985A2 Implantable interface system
12/21/2005EP1605982A2 Compositions for neuronal tissue regeneration
12/21/2005EP1605977A1 Pharmaceutical composition comprising fungal cell or fragment thereof
12/21/2005EP1605971A1 Immunogenic composition and methods
12/21/2005EP1605968A2 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
12/21/2005EP1605956A1 Administration of capsaicinoids
12/21/2005EP1605948A1 Prostaglandin compositions for the treatment of erectile dysfunction
12/21/2005EP1605945A1 Topical formulation and use of buspirone
12/21/2005EP1605931A1 Drug formulations having long and medium chain triglycerides
12/21/2005EP1605928A1 Compositions and methods for treatment of premature ejaculation
12/21/2005EP1605923A2 Mssn dispersion and method for producing the same
12/21/2005EP1605922A2 Temporary embolization using inverse thermosensitive polymers
12/21/2005EP1605921A1 Formulations comprising an active ingredient and cocoa powder and use thereof
12/21/2005EP1605920A1 Formulations comprising tolterodine and cocoa powder and use thereof
1 ... 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 ... 2991